Successfully completed a Phase 1 dose-escalation study demonstrating pan-mutant clinical activity, 95% target engagement and no grade 3 or 4 toxicities at doses as low as 5 mg BID Initiating an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback